None
Quote | Genmab A/S Dkk (OTCMKTS:GNMSF)
Last: | $245.33 |
---|---|
Change Percent: | -1.76% |
Open: | $245.33 |
Close: | $245.33 |
High: | $255.02 |
Low: | $242.1 |
Volume: | 247 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Genmab A/S Dkk (OTCMKTS:GNMSF)
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
Message Board Posts | Genmab A/S Dkk (OTCMKTS:GNMSF)
Subject | By | Source | When |
---|---|---|---|
Products in development | XenaLives | investorshub | 10/27/2019 2:32:31 PM |
Product pipeline | XenaLives | investorshub | 10/27/2019 2:32:00 PM |
About Genmab A/S | XenaLives | investorshub | 10/27/2019 2:25:49 PM |
$GMXAY largest holding in Blackrock fund: | XenaLives | investorshub | 10/27/2019 2:23:21 PM |
Genmab Announces Phase II Study of Daratumumab in | PennyStock Alert | investorshub | 09/16/2019 12:43:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...